Abstracts

An Infant bNAb With Low Somatic Hypermutation Contributes to Polyclonal Breadth

Rapid development of plasma cross-clade neutralization breadth has been described in infants compared to adults. The characteristics of infant HIV-specific antibodies contributing to plasma neutralization breadth have not yet been studied, but may provide unique insights into the process of developing HIV-1-specific broadly neutralizing antibody (bNAb) responses.  We isolated and characterized neutralizing antibodies (NAb) from an…

Virus, Host, and Disease Factors Govern HIV-1 Broadly Neutralizing Antibody Induction

Development of an effective AIDS vaccine that elicits broadly neutralizing antibodies (bnAbs) urgently awaits the identification of parameters that steer their induction. Here we report on a systematic analysis of bnAb activity in 4484 HIV-1 infected individuals designed to explore and identify viral, host and disease factors that affect bnAb generation. Plasma neutralization activity was…

Neutrophil Functions Induced by Gp-120 Specific IgA and IgG; Clues for Immunotherapy

While neutropenia has been associated with increased risk of HIV infection, the antiviral role of neutrophils in HIV infection has been poorly studied. However, neutrophil extracellular traps have been shown to capture HIV virions that were subsequently eliminated by myeloperoxidase and α-defensins. Moreover, neutrophils are the most abundant cells in the blood, the most rapid…

Potency and Kinetics of Autologous HIV-1 Neutralizing Antibody Responses During ATI

Studies utilizing brief analytical treatment interruption (ATI) of cART in HIV-1 infected subject have consistently shown that viral rebound occurs rapidly upon treatment interruption. The viral dynamics and relevant host immune pressures at this juncture, however, remain unclear. To test the hypothesis that the autologous antibody response is a significant driver of virus selection during…

PD-1 Blockade as an Adjunct Therapy to ART and Potential to Destabilize SIV Reservoir

The expression of the inhibitory receptor programmed death-1 (PD-1) on anti-viral CD8 T cells and virally infected CD4 T cells provides an immunological signature for both T cell dysfunction and viral latency during chronic SIV/HIV infection. We hypothesized that PD-1 blockade administered during the initiation of anti-retroviral therapy (ART) and under fully suppressive ART would…

Repeated TLR7 Agonist Treatment of SIV+ Monkeys on ART Can Lead to Viral Remission

The identification of pharmaceutical agents capable of safely reversing HIV-1 latentcy in ART-treated patients is urgently needed. We have previously reported that an oral TLR7 agonist GS-986, at doses that produce peripheral IFN-alpha, induces transient plasma viremia in SIV-infected rhesus macaques (RMs) on antiretroviral therapy (ART). In this follow up study, we assessed if lower clinically…

HIV-1 Combinectin BMS-986197: A Long-Acting Inhibitor With Multiple Modes of Action

Long-acting antiretrovirals could provide a useful alternative to daily oral therapy for HIV-1 infected individuals. However, the need for combination therapy and the potential for multiple IV/IM injections or tolerability issues may create roadblocks to this type of therapy. Adnectins are small proteins derived from the 10th type III domain of the human fibronectin protein…